RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Drug-Induced Dyskinesia
Accession: DOID:9008394
browse the term
Definition: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
Synonyms: exact_synonym: Drug-Induced Dyskinesias; Medication Induced Dyskinesia; Medication-Induced Dyskinesias
primary_id: MESH:D004409
xref: EFO:1000904
G
Abat
4-aminobutyrate aminotransferase
IMP
RGD
PMID:7740056 PMID:6445277
RGD:1598524 , RGD:10047091
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
G
Cacna1d
calcium voltage-gated channel subunit alpha1 D
IMP
RGD
PMID:18947822
RGD:6906919
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
G
Cat
catalase
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:19109989
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
G
Cck
cholecystokinin
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:2320253
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
G
Comt
catechol-O-methyltransferase
IMP
RGD
PMID:16437585
RGD:2289781
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
G
Cyp2d4
cytochrome P450, family 2, subfamily d, polypeptide 4
ISO
RGD
PMID:1673290
RGD:1358547
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
G
Dbn1
drebrin 1
IEP
levodopainduced; protein:increased expression:striatum:
RGD
PMID:23241013
RGD:10398811
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
G
Ddc
dopa decarboxylase
IEP
associated with Parkinson Disease; protein:decreased expression:striatum (rat)
RGD
PMID:20232137
RGD:5128860
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
G
Drd1
dopamine receptor D1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:7845605 PMID:10858612 PMID:16982285 PMID:19520364
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
G
Drd2
dopamine receptor D2
IDA ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:7845605 PMID:10534246 PMID:14629710 PMID:18707801
RGD:2311579
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
G
Drd3
dopamine receptor D3
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20945430
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
G
Egr1
early growth response 1
IEP
RGD
PMID:22153973
RGD:10395307
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
G
Fosb
FosB proto-oncogene, AP-1 transcription factor subunit
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:17219962
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
G
Gad1
glutamate decarboxylase 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:9767399
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
G
Gch1
GTP cyclohydrolase 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
G
Gdnf
glial cell derived neurotrophic factor
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:11168568
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
G
Glul
glutamate-ammonia ligase
IDA
RGD
PMID:6445277
RGD:10047091
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
G
Grk6
G protein-coupled receptor kinase 6
IMP
associated with Parkinson Disease
RGD
PMID:20410529
RGD:5684919
NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644
G
Gsk3b
glycogen synthase kinase 3 beta
treatment
IMP
associated with Parkinsonian Disorders
RGD
PMID:26997328
RGD:13792768
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
G
Homer1
homer scaffold protein 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:24126708
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
G
Htr1a
5-hydroxytryptamine receptor 1A
IMP
RGD
PMID:21352823
RGD:5683628
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
G
Mapt
microtubule-associated protein tau
treatment
IDA
associated with Parkinsonian Disorders
RGD
PMID:25511986
RGD:13800920
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
G
Mtor
mechanistic target of rapamycin kinase
treatment
IMP
associated with Parkinsonian Disorders
RGD
PMID:23938307
RGD:10040953
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
G
Pdyn
prodynorphin
treatment severity
ISO IEP HEP
CTD Direct Evidence: marker/mechanism associated with Parkinsonism associated with Parkinsonism;protein:increased expression:striatum
CTD RGD
PMID:9767399 PMID:21737418 PMID:10869049 PMID:17884291 PMID:21737418
RGD:401900134 , RGD:401851046 , RGD:401850563
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
G
Penk
proenkephalin
treatment disease_progression
IEP ISO
mRNA:increased expression:brain:striatum: associated with Parkinsonism associated with Parkinsonism;mRNA:increased expression:striatum CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:9767399 PMID:20456008 PMID:10869049 PMID:26113400
RGD:10003039 , RGD:401900134 , RGD:401851054
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
G
Ppp1r1b
protein phosphatase 1, regulatory (inhibitor) subunit 1B
treatment
IDA
associated with Parkinsonian Disorders
RGD
PMID:27771532
RGD:13514053
NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775
G
Rasgrf1
RAS protein-specific guanine nucleotide-releasing factor 1
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:21115823
NCBI chr 8:90,445,154...90,574,274
Ensembl chr 8:90,445,154...90,574,269
G
Rela
RELA proto-oncogene, NF-kB subunit
IEP
protein:increased expression:nucleus, brain
RGD
PMID:18590723
RGD:2298778
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
G
Rgs4
regulator of G-protein signaling 4
treatment
IMP
associated with Parkinsonian Disorders
RGD
PMID:24969021
RGD:13524515
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
G
Rgs9
regulator of G-protein signaling 9
ISO
CTD Direct Evidence: marker/mechanism|therapeutic
CTD
PMID:18160641 PMID:24663062
NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892
G
Th
tyrosine hydroxylase
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:15659429
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
treatment
ISO
associated with schizophrenia
RGD
PMID:10889552
RGD:1358545
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Drd3
dopamine receptor D3
ISO
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
G
Sod2
superoxide dismutase 2
ISO
associated with schizophrenia
RGD
PMID:12960753
RGD:1581250
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all